{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:17:24Z","timestamp":1794323844121,"version":"4.9.0"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Non\u2013muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression rates. Despite the effectiveness of Bacillus Calmette-Gu\u00e9rin (BCG) therapy after transurethral resection of bladder tumor (TURBT), BCG fails nearly 40% of patients, requiring alternative treatments. Traditionally, radical cystectomy has been the standard for BCG-unresponsive disease, although it significantly affects quality of life. Recent advances have focused on bladder-preserving therapies that leverage immune checkpoint inhibitors, viral gene therapies, novel drug delivery systems, and targeted molecular agents. Emerging approaches such as TAR-200 and UGN-102 offer novel intravesical delivery systems that enhance therapeutic efficacy while minimizing systemic adverse effects. Viral therapies, including nadofaragene firadenovec and CG0070, deliver immune-activating and oncolytic agents directly to urothelial tumor cells. Additionally, immune checkpoint inhibitors such as pembrolizumab and durvalumab have demonstrated potential for systemic treatments in BCG-unresponsive NMIBC and may show even more promise in combinations. Ongoing trials are expected to provide crucial data on these therapies' efficacy, particularly in high-risk and intermediate-risk populations. For low-grade NMIBC, efforts are underway to de-escalate care through active surveillance and novel adjuvant therapies, reducing the need for repeated TURBT procedures. Together, these advancements highlight a promising shift toward personalized, bladder-preserving strategies that prioritize patient quality of life while addressing unmet needs in NMIBC management.<\/jats:p>","DOI":"10.1200\/edbk-25-471942","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:59:06Z","timestamp":1739289546000},"source":"Crossref","is-referenced-by-count":36,"title":["New Treatment Options for Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1200","volume":"45","author":[{"given":"Mikolaj","family":"Filon","sequence":"first","affiliation":[{"name":"University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-1638","authenticated-orcid":true,"given":"Bogdana","family":"Schmidt","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","first-page":"43","article-title":"Non-muscle-invasive bladder cancer: Overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","volume":"22","author":"Matulewicz RS","year":"2020","unstructured":"Matulewicz RS, Steinberg GD: Non-muscle-invasive bladder cancer: Overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol 22:43-51, 2020","journal-title":"Rev Urol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01350-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_3_3_5_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 5.2024","author":"National Comprehensive Cancer Network","year":"2024","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 5.2024, 2024. https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.06.013"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.06.006"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002186"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003645"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004296"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.01.013"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841868909111193"},{"key":"e_1_3_3_14_2","unstructured":"ClinicalTrials.gov: Study of TAR-200 in participants with muscle-invasive bladder cancer who are unfit for curative-intent therapy (SUNRISE-1). https:\/\/clinicaltrials.gov\/study\/NCT04640623"},{"key":"e_1_3_3_15_2","volume-title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in Participants With BCG-Na\u00efve High-Risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in Participants With BCG-Na\u00efve High-Risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3). https:\/\/clinicaltrials.gov\/study\/NCT05714202"},{"key":"e_1_3_3_16_2","volume-title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Gu\u00e9rin (BCG) (SunRISe-5)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Gu\u00e9rin (BCG) (SunRISe-5). https:\/\/clinicaltrials.gov\/study\/NCT06211764"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6498-2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00178-5"},{"key":"e_1_3_3_21_2","volume-title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676). https:\/\/clinicaltrials.gov\/study\/NCT03711032"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.004"},{"key":"e_1_3_3_23_2","volume-title":"Atezolizumab Plus One-Year BCG Bladder Instillation in BCG-Naive High-Risk Non-Muscle Invasive Bladder Cancer Patients (ALBAN)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Atezolizumab Plus One-Year BCG Bladder Instillation in BCG-Naive High-Risk Non-Muscle Invasive Bladder Cancer Patients (ALBAN). https:\/\/clinicaltrials.gov\/study\/NCT03799835"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.017"},{"key":"e_1_3_3_25_2","volume-title":"BCG in Combination With Durvalumab in Adult BCG-Na\u00efve, High-Risk NMIBC Participants (PATAPSCO)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: BCG in Combination With Durvalumab in Adult BCG-Na\u00efve, High-Risk NMIBC Participants (PATAPSCO). https:\/\/clinicaltrials.gov\/study\/NCT05943106"},{"key":"e_1_3_3_26_2","volume-title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC). https:\/\/clinicaltrials.gov\/study\/NCT03528694"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0271"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6768"},{"key":"e_1_3_3_29_2","volume-title":"Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-muscle Invasive Bladder Cancer (Phase 1b) (ADVANCED-1)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-muscle Invasive Bladder Cancer (Phase 1b) (ADVANCED-1). https:\/\/clinicaltrials.gov\/study\/NCT05085990"},{"key":"e_1_3_3_30_2","unstructured":"Urology Times: Cell therapy TARA-002 shows initial promise in NMIBC. https:\/\/www.urologytimes.com\/view\/cell-therapy-tara-002-shows-initial-promise-in-nmibc"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003586"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_3_34_2","volume-title":"ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (ABLE-41)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (ABLE-41). https:\/\/clinicaltrials.gov\/study\/NCT06026332"},{"key":"e_1_3_3_35_2","volume-title":"Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With Adstiladrin","author":"Ferring Pharmaceuticals","unstructured":"Ferring Pharmaceuticals: Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With Adstiladrin. Nadofaragene Firadenovec, VNCG. https:\/\/ferringusa.com\/?press=ferring-adds-three-new-studies-to-non-muscle-invasive-bladder-cancer-clinical-trial-program-with-adstiladrin-nadofaragene-firadenovec-vncg"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1059"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"e_1_3_3_38_2","volume-title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003). https:\/\/clinicaltrials.gov\/study\/NCT04452591"},{"key":"e_1_3_3_39_2","unstructured":"UroToday: AUA 2024: Pivotal results from BOND-003 a phase 3 single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer. 2024. https:\/\/www.urotoday.com\/conference-highlights\/aua-2024\/aua-2024-bladder-cancer\/151709-aua-2024-pivotal-results-from-bond-003-a-phase-3-single-arm-study-of-intravesical-cretostimogene-grenadenorepvec-for-the-treatment-of-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html"},{"key":"e_1_3_3_40_2","volume-title":"Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001). https:\/\/clinicaltrials.gov\/study\/NCT04387461"},{"key":"e_1_3_3_41_2","unstructured":"CG Oncology: CG Oncology presents positive final results from Phase 2 CORE-001 study of CG0070 in high-risk BCG-unresponsive non-muscle invasive bladder cancer. 2024. https:\/\/ir.cgoncology.com\/news-releases\/news-release-details\/cg-oncology-present-positive-final-results-phase-2-core-001"},{"key":"e_1_3_3_42_2","volume-title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC. https:\/\/clinicaltrials.gov\/study\/NCT06567743"},{"key":"e_1_3_3_43_2","volume-title":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT. https:\/\/clinicaltrials.gov\/study\/NCT06111235"},{"key":"e_1_3_3_44_2","unstructured":"UroToday: IBCN 2024: EG-70 (delatimogene voraplasmid) a novel non-viral intravesical gene therapy for BCG-unresponsive NMIBC with CIS: Preclinical characterization and translation into the clinic. 2024. https:\/\/www.urotoday.com\/conference-highlights\/ibcn-2024\/155101-ibcn-2024-eg-70-detalimogene-voraplasmid-a-novel-non-viral-intravesical-gene-therapy-for-bcg-unresponsive-nmibc-with-cis-preclinical-characterization-and-translation-into-the-clinic.html"},{"key":"e_1_3_3_45_2","volume-title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Na\u00efve","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Na\u00efve. https:\/\/clinicaltrials.gov\/study\/NCT04752722"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.020"},{"key":"e_1_3_3_47_2","unstructured":"UroToday: AUA 2020: Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer. 2020. https:\/\/www.urotoday.com\/conference-highlights\/aua-2020\/aua-2020-bladder-cancer\/122653-aua-2020-phase-3-results-of-vicinium-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html"},{"key":"e_1_3_3_48_2","volume-title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG). https:\/\/clinicaltrials.gov\/study\/NCT03258593"},{"key":"e_1_3_3_49_2","unstructured":"UroToday: AUA 2021: Interim analysis of a phase I single-arm study of the combination of durvalumab and Vicinium in subjects with high-grade NMIBC previously treated with BCG. 2021. https:\/\/www.urotoday.com\/conference-highlights\/aua-2021-program\/aua-2021-bladder-cancer\/131953-aua-2021-interim-analysis-of-a-phase-i-single-arm-study-of-the-combination-of-durvalumab-and-vicineum-in-subjects-with-high-grade-nmibc-previously-treated-with-bcg.html"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3817"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64665-2"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3116"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-471942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:59:27Z","timestamp":1762376367000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-471942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1200\/EDBK-25-471942"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-471942","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"e471942"}}